A Phase 1 Open-Label Safety Pharmacokinetic and Preliminary Efficacy Study of STRO-002 An Anti-Folate Receptor alpha Antibody- Drug Conjugate (ADC) In Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

Study Overview

This study has two parts: Part 1 (dose escalation) and Part 2 (dose expansion). The purpose of Part 1 is to determine: What effects, good and/or bad, STRO-002 has on subjects and their disease The highest dose of STRO-002 that can be safely given to subjects using a pre-defined starting dose and rules for increasing the dose The dose of STRO-002 that has the best overall safety profile. This includes collection of side effects and measured amounts of STRO-002 in the blood at different time points, known as pharmacokinetics (PK) testing. This dose, the recommended phase 2 dose (RP2D), will be used in Part 2 of this study. Levels (if any) of antibodies in the blood which may arise in response to study drug known as anti-drug antibodies (ADA) During Part 2, subjects will be dosed at the applicable RP2D selected from Part 1 of the study. The purpose of Part 2 is to determine: What effects, good and/or bad, STRO-002 has on subjects including ADA as defined above How their cancer responds to treatment with STRO-002 The amount of STRO-002 in the blood at different times (PK) Key Eligibility

  • Study Identifier: 833962

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu